Swiss drugmaker Novartis AG has signed a licensing agreement with China's Abogen Biosciences worth up to $7.8 billion to advance RNA-based therapies. Novartis will pay $575 million upfront for exclusive rights to ABO2203, an experimental mRNA-encoded T-cell engager designed to treat autoimmune diseases like lupus and rheumatoid arthritis by targeting B cells. Abogen can earn up to $7.2 billion more in development and regulatory milestones.
Scope of the licensing agreement
- ▪Swiss drugmaker Novartis AG signed a licensing agreement with Chinese biotech company Abogen Biosciences on October 2, 2026, to advance RNA-based therapies
- ▪Under a licensing agreement with Abogen Biosciences signed on October 2, 2026, Novartis AG secured options to license additional experimental medicines developed using Abogen Biosciences' RNA technology platform
- ▪Under the agreement signed on October 2, 2026, Novartis AG will gain exclusive rights to Abogen Biosciences' experimental drug ABO2203
Mechanism and targets of ABO2203
- ▪ABO2203, the experimental autoimmune therapy licensed by Novartis AG, is an mRNA-encoded T-cell engager designed to make the patient's body produce the therapeutic molecule
- ▪The experimental drug ABO2203 is designed to treat autoimmune diseases, such as lupus and rheumatoid arthritis, by targeting B cells
Financial terms of the agreement
- ▪The licensing deal between Novartis AG and Abogen Biosciences, signed October 2, 2026, is valued at up to approximately $7.8 billion, including $575 million upfront and $7.2 billion in milestones for ABO2203
- ▪Under a licensing agreement with Novartis AG signed on October 2, 2026, Abogen Biosciences will receive up to $7.2 billion in milestone payments from Novartis AG if ABO2203 advances through development and wins regulatory approval
Debatable claims
- ▪Autoimmune diseases are the most promising application for next-generation mRNA
- ▪mRNA-encoded therapies are a viable treatment for chronic autoimmune diseases
- ▪Western drugmakers should avoid licensing therapeutic platforms from Chinese biotech firms
Story comments
Loading comments…